A HIF-1 network reveals characteristics of epithelial-mesenchymal transition in acute promyelocytic leukemia

Genome Medicine

Volumn 6, Issue 12, 2014, Pages

  Percio, Stefano ^a   Coltella, Nadia ^b   Grisanti, Sara ^a   Bernardi, Rosa ^b   Pattini, Linda ^a  

^a POLITECNICO DI MILANO   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MICRORNA;

ACUTE MYELOBLASTIC ANEMIA; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA;

EID: 84927752378     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-014-0084-4     Document Type: Article

References (45)

1. Estey E, Döhner H: Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
2. Wang Z-Y, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
3. Lu X, Kang Y: Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
4. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000, 88:2606-2618.
5. Semenza GL: HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013, 123:3664-3671.
6. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y: Targeting HIF1a eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411.
7. Zhang H, Li H, Xi HS, Li S: HIF1a is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 2012, 119:2595-2607.
8. Coltella N, Percio S, Valsecchi R, Cuttano R, Guarnerio J, Ponzoni M, Pandolfi PP, Melillo G, Pattini L, Bernardi R: HIF factors cooperate with PML-RARa to promote acute promyelocytic leukemia progression and relapse. EMBO Mol Med 2014, 6:640-650.
9. Hartemink AJ: Reverse engineering gene regulatory networks. Nat Biotechnol 2005, 23:554-555.
10. Floratos A, Smith K, Ji Z, Watkinson J, Califano A: geWorkbench: an open source platform for integrative genomics. Bioinformatics 2010, 26:1779-1780.
11. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504.
12. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS: MicroRNA targets in Drosophila. Genome Biol 2003, 5:R1.
13. Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
14. Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37:1-13.
15. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albaek C, Schrøder H, Ørum H: A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008, 7:3598-3608.
16. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000, 25:217-222.
17. Valk PJM, Verhaak RGW, Beijen MA, Erpelinck CAJ, Barjesteh Van Waalwijk Van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
18. Baldi P, Brunak S: Bioinformatics: The Machine Learning Approach (Adaptive Computation and Machine Learning). 2nd edition. A Bradford Book: The MIT Press, Cambridge, Massachusetts, London, England; 2001.
19. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A: Reverse engineering of regulatory networks in human B cells. Nat Genet 2005, 37:382-390.
20. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu C-G, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B: Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945-3950.
21. Lu X, Jain VV, Finn PW, Perkins DL: Hubs in biological interaction networks exhibit low changes in expression in experimental asthma. Mol Syst Biol 2007, 3:98.
22. Stefanidakis M, Koivunen E: Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006, 108:1441-1450.
23. Wu JJ, Cantor A, Moscinski LC: beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res 2007, 31:49-57.
24. Spijkers PPEM, da Costa MP, Westein E, Gahmberg CG, Zwaginga JJ, Lenting PJ: LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion. Blood 2005, 105:170-177.
25. Perrot G, Langlois B, Devy J, Jeanne A, Verzeaux L, Almagro S, Sartelet H, Hachet C, Schneider C, Sick E, David M, Khrestchatisky M, Emonard H, Martiny L, Dedieu S: LRP-1-CD44, a new cell surface complex regulating tumor cell adhesion. Mol Cell Biol 2012, 32:3293-3307.
26. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res 2008, 58:262-270.
27. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ESJM: The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, for example, acute leukemia. Crit Rev Oncol Hematol 2004, 50:87-100.
28. King-Underwood L, Pritchard-Jones K: Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998, 91:2961-2968.
29. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997, 90:1217-1225.
30. Leegwater PA, Yuan BQ, van der Steen J, Mulders J, Könst AA, Boor PK, Mejaski-Bosnjak V, van der Maarel SM, Frants RR, Oudejans CB, Schutgens RB, Pronk JC, van der Knaap MS: Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts. Am J Hum Genet 2001, 68:831-838.
31. Holmes KM, Annala M, Chua CYX, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, Hess K, Fuller GN, Zhang W: Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci U S A 2012, 109:3475-3480.
32. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW: Integrinmediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004, 32:859-868.
33. Wang H, Shen W, Huang H, Hu L: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasionenhancing genes. Cancer Res 2003, 63:4315-4321.
34. Chen X, Zheng J, Zou Y, Song C, Hu X, Zhang C: IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells. J Hematol Oncol 2013, 6:72.
35. Lin Z-Y, Chuang W-L: Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother 2012, 66:454-458.
36. Fink JK, Jones SM, Esposito C, Wilkowski J: Human microtubule-associated protein 1a (MAP1A) gene: genomic organization, cDNA sequence, and developmental-and tissue-specific expression. Genomics 1996, 35:577-585.
37. Goossens S, Haigh J: The role of EMT modulators in hematopoiesis and leukemic transformation. In Hematol Sci Pract. Edited by Lawrie C, InTech. 2012:101-120. doi:10.5772/34816 ISBN 978-953-51-0174-1 http://www. intechopen.com/books/hematology-science-and-practice/-the-role-of-emtmodulators-in-hematopoiesis-and-leukemic-transformation.
38. Guarino M, Rubino B, Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318.
39. Yilmaz M, Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28:15-33.
40. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
41. Payton J, Grieselhuber N: High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest 2009, 119:1714-1726.
42. Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M, Fang H, Mi J, Yang X, Xiao H, Minden M, Du Y, Chen Z, Zhang J: PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 2010, 17:186-197.
43. Daschkey S, Röttgers S, Giri A, Bradtke J, Teigler-Schlegel A, Meister G, Borkhardt A, Landgraf P: MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AMLrelevant pathways. PLoS One 2013, 8:e56334.
44. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, Ramakrishnan S: Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-a isoforms and promotes angiogenesis. J Clin Invest 2010, 120:4141-4154.
45. Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, Di Feo A: microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014, 5:2977.